Hostname: page-component-7c8c6479df-995ml Total loading time: 0 Render date: 2024-03-28T23:52:23.456Z Has data issue: false hasContentIssue false

Cannabis and psychosis

Published online by Cambridge University Press:  02 January 2018

Jonathan Ornstein*
Affiliation:
Ealing Early Intervention in Psychosis Service, West London Mental Health Trust, The Green, Southall, Middlesex UB2 4BH. Email: Jonathan.Ornstein@wlmht.nhs.uk; James Stone, Centre for Mental Health, Imperial College London, UK
Rights & Permissions [Opens in a new window]

Abstract

Type
Columns
Copyright
Copyright © Royal College of Psychiatrists, 2010 

We read with interest the recent study by Henquet and colleagues. Reference Henquet, van Os, Kuepper, Delespaul, Smits and Campo1 As well as providing further support for the well-established theory that cannabis may worsen or re-awaken psychosis in vulnerable adults, this study reports the fascinating and novel finding that cannabis appears to differentially affect mood – with patients with a psychotic disorder, but not controls, reporting improvements in negative affect following cannabis use. On the other hand, cannabis enhanced positive affect in patients and controls alike.

Previous studies have been contradictory regarding the effects of regular cannabis use on mood. Denson & Earleywine found that regular users reported less depressed mood and more positive affect than non-users, Reference Degenhardt, Hall and Lynskey2 whereas Degenhardt and colleagues reported that heavy cannabis use and depression were associated. Reference Denson and Earleywine3 The reason for these differences is not clear, but may be due to differences in cannabis composition, as pure delta-9-tetrahydrocannabinol is anxiogenic when given acutely, whereas cannabidiol appears to ameliorate these effects. Reference Bhattacharyya, Morrison, Fusar-Poli, Martin-Santos, Borgwardt and Winton-Brown4

The finding that patients derived more benefit from cannabis use in terms of mood suggests that the association of early cannabis use with subsequent onset of psychosis may not, in fact, be a causative relationship as previously reported. Reference Moore, Zammit, Lingford-Hughes, Barnes, Jones and Burke5 Rather, early cannabis use in these (already vulnerable) individuals may be more likely as they derive more benefit – in terms of mood enhancement – than individuals who are not at risk of psychosis. Henquet and colleagues also report that the effects on mood are acute, whereas effects on psychosis are subacute. It would be interesting to determine whether the effects on mood and psychosis occur with equal frequency earlier in the illness, because if psychosis emerges only with repeated dosing, this may be a further maintaining factor in early use.

Regardless of the aetiological relationship of cannabis use to psychosis onset, this study highlights an important point – people take cannabis because they feel that they derive benefit from it, and patients with psychosis are no different in this respect. In terms of clinical practice, this paper highlights one reason why service users may continue to smoke cannabis, despite the fact that it clearly worsens their psychotic symptoms. This awareness can add to our understanding and attitude towards the service user, and enable us more creatively to help the service user find alternative ways to boost their mood.

Footnotes

Edited by Kiriakos Xenitidis and Colin Campbell

References

1 Henquet, C, van Os, J, Kuepper, R, Delespaul, P, Smits, M, à Campo, J, et al. Psychosis reactivity to cannabis use in daily life: an experience sampling study. Br J Psychiatry 2010; 196: 447–53.Google Scholar
2 Degenhardt, L, Hall, W, Lynskey, M. Exploring the association between cannabis use and depression. Addiction 2003; 98: 1493–504.CrossRefGoogle ScholarPubMed
3 Denson, TF, Earleywine, M. Decreased depression in marijuana users. Addict Behav 2006; 31: 738–42.Google Scholar
4 Bhattacharyya, S, Morrison, PD, Fusar-Poli, P, Martin-Santos, R, Borgwardt, S, Winton-Brown, T, et al. Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. Neuropsychopharmacology 2010; 35: 764–74.CrossRefGoogle ScholarPubMed
5 Moore, TH, Zammit, S, Lingford-Hughes, A, Barnes, TR, Jones, PB, Burke, M, et al. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet 2007; 370: 319–28.CrossRefGoogle ScholarPubMed
Submit a response

eLetters

No eLetters have been published for this article.